Peter Zage is an Oncology physician affiliated with University of California San Diego. OpenAlex indexes 135 publications with 2,517 citations (h-index 31); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3010 Childrens Way, 2 West
San Diego, CA 921234223
Telephone
858-966-5811Registry record last updated 22 Apr 2016.
Clinical trials
- Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma
Sponsor: Children's Oncology Group
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- USWM, LLCProgram year20252 payments
- HEMA Biologics, LLCProgram year20251 payment
- Y-mAbs Therapeutics, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2016–2017 per NIH RePORTER. The latest:
- The Role of Growth Factor Receptor Trafficking in Tumorigenesis
University of California, San Diego
FY2017$315,213R01CA166749 - The Role of Growth Factor Receptor Trafficking in Tumorigenesis
University of California, San Diego
FY2016$325,983R01CA166749
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - USP7 Inhibition Suppresses Neuroblastoma Growth via Induction of p53-Mediated Apoptosis and EZH2 and N-Myc Downregulation
International Journal of Molecular Sciences
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Jay Giedd, MD
University of California San Diego
Robert Weinreb, MD
University of California San Diego
Dilip Jeste, MD
University of California San Diego
Igor Grant, MD
University of California San Diego
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”